SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BCDA reported Third Quarter 2026 results. The price and volatility reaction is pending.
BCDAearnings

Earnings reactions, page 3

BioCardia, Inc. (BCDA) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss was $1.8 million (or $1,817 thousand) for the three months ended September 30, 2026, compared to $1.5 million (or $1,483 thousand) for the three months ended September 30, 2025.
  • Basic and diluted net loss per share was $0.12 for the three months ended September 30, 2026, compared to $0.24 for the three months ended September 30, 2025.
  • Research and development expenses were $1.2 million for the three months ended September 30, 2026, compared to $936,000 in the three months ended September 30, 2025.
  • Selling, general and administrative expenses were $600,000 in the three months ended September 30, 2026, compared to $552,000 in the three months ended September 30, 2025.
  • Net cash used in operations for the three months ended September 30, 2026 was $1.7 million, comparable to $1.7 million for the three months ended September 30, 2025.
  • Cash and cash equivalents totaled $2.2 million as of September 30, 2026.

Guidance

  • Cash and cash equivalents of $2.2 million as of September 30, 2026, are anticipated to provide runway into 2027.
  • The company expects to complete the Helix De Novo submission in the first quarter of 2027 with approval in mid-2027 if the FDA meets its official target goal of 150 review days under MDUFA guidelines.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →